Indications and use of, and incidence of major bleeding with, antithrombotic agents in myelodysplastic syndrome

Marc Sorigue, Javier Nieto, Mireia Santos-Gomez, Edurne Sarrate, Maria José Jiménez, Cristian Morales-Indiano, Laia Lopez-Viaplana, Elisa Orna, Jose Tomas Navarro, Josep Maria Ribera, Blanca Xicoy

Sortida de recercaRecerca

Resum

© 2018 Elsevier Ltd Myelodysplastic syndrome (MDS) and antithrombotic medication both increase the risk of bleeding. We set out to analyze the prevalence of use, indications and bleeding risk of antithrombotic therapy in patients with MDS in a retrospective, single-center study including all patients with MDS with >20 × 10 9 /L platelets. 193 patients (59% male, median age 75 years) were included; 122 did not receive antithrombotic treatment, 51 received antiplatelet agents and 20 received anticoagulants. The cumulative incidence of major bleeding was higher in both the antiplatelet group (11.8% at 4 years, 95% confidence interval [95%CI]: 4.7–22.3%) and the anticoagulation group (21.2% at 4 years, 95%CI 6–42.5%) than in the control group (2.8% at 4 years 95%CI: 0.7–7.3%). The prevalence of use of antithrombotic medication in this cohort of patients with MDS was high and bleeding risk was increased in these patients.
Idioma originalEnglish
Pàgines (de-a)24-28
RevistaLeukemia Research
Volum73
DOIs
Estat de la publicacióPublicada - 1 d’oct. 2018

Empremta digital Navegar pels temes de recerca de 'Indications and use of, and incidence of major bleeding with, antithrombotic agents in myelodysplastic syndrome'. Junts formen una empremta única.

Citeu això